Table 3.
Factors associated with progression-free survival or overall survival in univariate and multivariate analyses.
| Factor | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Progression-free survival | ||||
| Age | 1.00 (0.98–1.01) | 0.62 | 1.00 (0.98–1.01) | 0.63 |
| Male sex | 0.79 (0.55–1.15) | 0.22 | 0.91 (0.61–1.37) | 0.66 |
| Immunocompromised | 1.03 (0.7–1.51) | 0.89 | 1.15 (0.76–1.76) | 0.5 |
| ECOG PS ≥ 2 | ||||
| ≤6 months | 2.3 (1.53–3.44) | <0.0001 | 2.33 (1.52–3.55) | 0.0001 |
| 6 months | 0.88 (0.31–2.51) | 0.81 | 0.85 (0.3–2.46) | 0.77 |
| Chronic dermatitis | 1.67 (1.02–2.71) | 0.04 | 1.07 (0.61–1.87) | 0.8 |
| Primary head-or-neck CSCC | 0.58 (0.41–0.81) | 0.0002 | 0.52 (0.34–0.79) | 0.0025 |
| Localized disease | 1.16 (0.82–1.64) | 0.41 | 0.72 (0.49–1.05) | 0.09 |
| Previous systemic treatment | 0.88 (0.62–1.23) | 0.44 | 1.03 (0.71–1.50) | 0.88 |
| Overall survival | ||||
| Age | 1.00 (0.99–1.02) | 0.81 | 0.99 (0.98–1.01) | 0.46 |
| Male sex | 0.9 (0.56–1.44) | 0.66 | 1.01 (0.61–1.67) | 0.97 |
| Immunocompromised | 0.82 (0.49–1.35) | 0.43 | 0.91 (0.53–1.56) | 0.72 |
| ECOG PS ≥ 2 | ||||
| ≤6 months | 4.39 (2.62–7.33) | <0.0001 | 4.56 (2.64–7.85) | 0.0001 |
| >6 months | 1.61 (0.61–4.27) | 0.34 | 1.69 (0.63–4.52) | 0.3 |
| Chronic dermatitis | 0.98 (0.49–1.95) | 0.95 | 0.7 (0.32–1.51) | 0.36 |
| Primary head-or-neck CSCC | 0.76 (0.49–1.18) | 0.22 | 0.67 (0.4–1.13) | 0.13 |
| Localized disease | 1.02 (0.66–1.58) | 0.94 | 0.74 (0.45–1.2) | 0.22 |
| Previous systemic treatment | 0.76 (0.5–1.17) | 0.21 | 1.09 (0.68–1.76) | 0.72 |
ECOG PS, Eastern Cooperative Oncology Group performance status; CSCC, cutaneous squamous-cell carcinoma.